Can TNF rs1800629 AG increase inflammatory responsiveness and amplify arachidonic-acid eicosanoid production?

Genetic variations in the tumor necrosis factor (TNF) gene can significantly alter an individual’s systemic inflammatory profile and downstream lipid mediator pathways.

Genetic influence on TNF expression

• The TNF rs1800629 polymorphism involves a G-to-A substitution at position -308 in the gene's promoter region, where the -308A allele acts as a high-producer variant.
• Individuals carrying the heterozygous AG genotype exhibit an intermediate-to-high TNF-alpha production profile. This genotype drives significantly higher transcriptional activity and inducible TNF-alpha expression compared to homozygous GG carriers, particularly under physiological, immune, or metabolic stress.

Mechanistic cascade of eicosanoid amplification

• Elevated TNF-alpha triggers intracellular signaling pathways, primarily activating NF-kappaB and mitogen-activated protein kinases (MAPKs) such as p38 and ERK. NF-kappaB translocates to the nucleus and directly binds response elements on the COX-2 (PTGS2) promoter, inducing its expression in epithelial cells, smooth muscle cells, and fibroblasts.
• Simultaneously, TNF signaling activates phospholipase A2 (PLA2), which hydrolyzes membrane phospholipids to release free arachidonic acid.
• This dual action—increasing substrate availability via PLA2 and upregulating the rate-limiting enzyme COX-2—drives the rapid metabolic conversion of arachidonic acid into prostaglandin H2 (PGH2) and downstream inflammatory eicosanoids, particularly PGE2.

Bottom line

• Bottom line: The TNF rs1800629 AG genotype genetically predisposes individuals to heightened inflammatory responsiveness. When triggered, elevated TNF-alpha signaling activates NF-kappaB and MAPK pathways to induce COX-2 expression, while concurrently activating PLA2 to mobilize arachidonic acid, collectively amplifying the production of pro-inflammatory eicosanoids.